Wedbush Expects Lower Earnings for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Investment analysts at Wedbush decreased their Q1 2026 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a research report issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings of $1.10 per share for the quarter, down from their prior forecast of $1.31. Wedbush has a "Outperform" rating on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences' Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.58 EPS and Q4 2026 earnings at $1.68 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The firm had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Neurocrine Biosciences's revenue was up 11.1% on a year-over-year basis. During the same period last year, the business earned $1.20 EPS.

Other equities research analysts have also issued research reports about the stock. Evercore ISI dropped their price objective on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Bank of America dropped their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. BMO Capital Markets boosted their price objective on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a research note on Tuesday, May 6th. Guggenheim boosted their price objective on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $150.00 target price (down from $185.00) on shares of Neurocrine Biosciences in a report on Friday, March 7th. Three analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and an average target price of $162.00.

Neurocrine Biosciences Stock Down 1.9%

Shares of NBIX traded down $2.25 during trading hours on Thursday, reaching $118.18. 698,905 shares of the company traded hands, compared to its average volume of 1,116,360. The company's fifty day moving average price is $106.36 and its two-hundred day moving average price is $121.93. The company has a market capitalization of $11.70 billion, a price-to-earnings ratio of 35.92, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $157.98.

Institutional Trading of Neurocrine Biosciences

Large investors have recently bought and sold shares of the business. Dodge & Cox lifted its stake in shares of Neurocrine Biosciences by 134.2% in the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock worth $411,742,000 after acquiring an additional 1,728,605 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at approximately $115,193,000. Wellington Management Group LLP lifted its position in shares of Neurocrine Biosciences by 102.9% during the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock valued at $198,939,000 after acquiring an additional 739,199 shares during the period. Thrivent Financial for Lutherans raised its position in shares of Neurocrine Biosciences by 2,759.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company's stock worth $100,705,000 after purchasing an additional 711,970 shares during the last quarter. Finally, Orbimed Advisors LLC grew its stake in Neurocrine Biosciences by 210.4% in the 4th quarter. Orbimed Advisors LLC now owns 938,120 shares of the company's stock worth $128,053,000 after acquiring an additional 635,900 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Transactions at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 2,558 shares of the stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.86, for a total value of $298,927.88. Following the transaction, the chief financial officer now directly owns 34,775 shares of the company's stock, valued at $4,063,806.50. This trade represents a 6.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Julie Cooke sold 1,551 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $116.78, for a total transaction of $181,125.78. Following the sale, the insider now owns 19,544 shares of the company's stock, valued at approximately $2,282,348.32. This represents a 7.35% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,953 shares of company stock worth $4,467,990. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences announced that its Board of Directors has authorized a share repurchase program on Friday, February 21st that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its shares are undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.